Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
Autore:
Holmberg, LA; Boeckh, M; Hooper, H; Leisenring, W; Rowley, S; Heimfeld, S; Press, O; Maloney, DG; McSweeney, P; Corey, L; Maziarz, RT; Appelbaum, FR; Bensinger, W;
Indirizzi:
Univ Washington, Clin Div, Fred Hutchinson Canc Res Ctr, Sch Med,Dept Med,Clin Div, Seattle, WA 98109 USA Univ Washington Seattle WA USA 98109 Med,Clin Div, Seattle, WA 98109 USA Puget Sound Oncol Consortium, Seattle, WA USA Puget Sound Oncol Consortium Seattle WA USA Consortium, Seattle, WA USA
Titolo Testata:
BLOOD
fascicolo: 12, volume: 94, anno: 1999,
pagine: 4029 - 4035
SICI:
0006-4971(199912)94:12<4029:IIOCDA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE CHEMOTHERAPY; BONE-MARROW TRANSPLANTATION; MULTIPLE-MYELOMA; CD34(+) CELLS; HEMATOPOIETIC PROGENITORS; POSITIVE SELECTION; PP65 ANTIGENEMIA; VIRUS INFECTION; BREAST-CANCER; PLASMA-CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Holmberg, LA Univ Washington, Clin Div, Fred Hutchinson Canc Res Ctr, Sch Med,Dept Med,Clin Div, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USAUniv Washington 1100 Fairview Ave N,POB 19024 Seattle WA USA 98109
Citazione:
L.A. Holmberg et al., "Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation", BLOOD, 94(12), 1999, pp. 4029-4035

Abstract

High-dose therapy with autologous peripheral blood stem cell (PBSC) rescueis widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34-selected autologous PBSC were assessed for the development of CMV diseasein the first 100 days posttransplant, Seven patients (22.6%) developed CMVdisease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths. (C) 1999 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 22:52:15